Jonathan D. Cheng

Suggest Changes
Learn More
BACKGROUND Patients with recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour activity of(More)
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1)(More)
5009 Background:  Options for women with recurrent endometrial cancer (EC) are limited. Clinical studies suggest mTOR inhibitors such as R have activity in this disease. This trial evaluated activity(More)
PURPOSE The feasibility of combining concomitant boost-accelerated radiation regimen (AFX-C) with cisplatin was previously demonstrated in this Phase II trial. This article reports the long-term(More)